Chorionic Gonadotropin (Human)
- Generic Name
- Chorionic Gonadotropin (Human)
- Brand Names
- Novarel, Pregnyl
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9002-61-3
- Unique Ingredient Identifier
- 20ED16GHEB
- Background
Human chorionic gonadotropin (HCG), a polypeptide hormone produced by the human placenta. Endogenously produced HCG interacts with the LHCG receptor of the ovary and promotes the maintenance of the corpus luteum during the beginning of pregnancy. This allows the corpus luteum to continuously secrete the hormone progesterone during the first trimester, which ...
- Indication
For the treatment of prepubertal cryptorchidism (not due to anatomical obstruction), for the treatment of selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males and for the induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to ...
- Associated Conditions
- Idiopathic Hypogonadotropic Hypogonadism, Undescended Testis, Secondary Hypogonadotrophic hypogonadism
- Associated Therapies
- Ovulation induction therapy, Stimulation of spermatogenesis therapy
Frozen Embryo Transfer (FET) in Natural Cycles or in Natural Cycles Controlled by Human Chorionic Gonadotropin (hCG) Administration
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 150
- Registration Number
- NCT00809107
- Locations
- 🇧🇪
Centre of Reproductive Medicine, Brussel, Belgium
Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women
- First Posted Date
- 2008-12-16
- Last Posted Date
- 2008-12-16
- Lead Sponsor
- New York Presbyterian Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT00808522
- Locations
- 🇺🇸
New York Downtown Hospital, New York, New York, United States
Low Dose hCG in the Late Follicular Phase
- Conditions
- Interventions
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2010-10-11
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 70
- Registration Number
- NCT00750100
- Locations
- 🇧🇪
UZ Brussel, Laarbeeklaan 101, Brussels, Belgium
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)
- Conditions
- Interventions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 541
- Registration Number
- NCT00703014
Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)
- Conditions
- Interventions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 344
- Registration Number
- NCT00702273
Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles
- Conditions
- Interventions
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Regionshospitalet Viborg, Skive
- Target Recruit Count
- 384
- Registration Number
- NCT00627406
- Locations
- 🇩🇰
The Fertility Clinic, Regional Hospital of Skive, Skive, Denmark
Synchronization of Follicle Wave Emergence and Ovarian Stimulation
- Conditions
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- University of Saskatchewan
- Target Recruit Count
- 80
- Registration Number
- NCT00439829
- Locations
- 🇨🇦
Genesis Fertility Centre, Vancouver, British Columbia, Canada
🇨🇦Department of Obstetrics, Gynecology and Reproductive Sciences, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.